drugset / Trial / NCT00421434
Study of Nitazoxanide, Peginterferon, and Ribavirin Combination Therapies in the Treatment of Chronic Hepatitis C
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of nitazoxanide-peginterferon and nitazoxanide-peginterferon-ribavirin combination regimens compared to the standard of care (peginterferon-ribavirin) in treating chronic hepatitis C genotype 4. The study will also evaluate the effect of the studied treatment regimens on end of treatment virologic response, ALT normalization and safety parameters.
Timeline
- Start
- 2006-06
- Primary completion
- 2008-09
- Completion
- 2008-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nitazoxanide | Other / unclassified | 500 mg | Oral |
| Comparator | Ribavirin | Small molecule | 1000 mg | Oral |
| Comparator | Ribavirin | Small molecule | 1200 mg | Oral |
| Comparator | Peginterferon alfa-2a | Protein / enzyme biologic | 180 ug | Other |